Robert Trenschel - Feb 8, 2024 Form 4 Insider Report for PALISADE BIO, INC. (PALI)

Role
Director
Signature
/s/ Robert Trenschel
Stock symbol
PALI
Transactions as of
Feb 8, 2024
Transactions value $
$0
Form type
4
Date filed
2/13/2024, 03:08 PM
Previous filing
Nov 24, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PALI Common Stock, par value $0.01 Options Exercise $0 +5.1K $0.00 5.1K Feb 8, 2024 Direct F1
transaction PALI Common Stock, par value $0.01 Options Exercise $0 +5.82K +114.12% $0.00 10.9K Feb 8, 2024 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PALI Restricted Stock Units Options Exercise $0 -5.1K -100% $0.00* 0 Feb 8, 2024 Common Stock 5.1K Direct F3, F5
transaction PALI Restricted Stock Units Options Exercise $0 -5.82K -100% $0.00* 0 Feb 8, 2024 Common Stock 5.82K Direct F4, F5
transaction PALI Common Stock Options Options Exercise $0 -12.2K -100% $0.00* 0 Feb 8, 2024 Common Stock 12.2K $1.60 Direct F6, F7
transaction PALI Common Stock Options Options Exercise $0 +12.2K $0.00 12.2K Feb 8, 2024 Common Stock 12.2K $1.60 Direct F6, F7
transaction PALI Common Stock Options Options Exercise $0 -6.88K -100% $0.00* 0 Feb 8, 2024 Common Stock 6.88K $0.59 Direct F6, F8
transaction PALI Common Stock Options Options Exercise $0 +6.88K $0.00 6.88K Feb 8, 2024 Common Stock 6.88K $0.59 Direct F6, F8
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Robert Trenschel is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id Content
F1 Represents the issuance of common stock upon the vesting and settlement of outstanding restricted stock units granted on June 11, 2023, resulting from the full accelerated vesting in connection with Reporting Person's resignation from the Issuer's Board of Directors.
F2 Represents the issuance of common stock upon the vesting and settlement of outstanding restricted stock units granted on November 21, 2023, resulting from the full accelerated vesting in connection with Reporting Person's resignation from the Issuer's Board of Directors.
F3 This restricted stock unit was granted on June 11, 2023 and pursuant to the issuance upon full vesting as described in Footnote 1, is no longer outstanding.
F4 This restricted stock unit was granted on November 21, 2023 and pursuant to the issuance upon full vesting described in Footnote 2, is no longer outstanding.
F5 Each restricted stock unit represents the right to receive one share of common stock.
F6 Each option represents the right to purchase one share of common stock at the exercise price.
F7 Represents the modification of the option granted on June 11, 2023, resulting in (i) immediate vesting in full of the outstanding grant and (ii) extension of the exercise period until the expiration date in connection with Reporting Person's resignation from the Issuer's Board of Directors.
F8 Represents the modification of the option granted on November 21, 2023, resulting in (i) immediate vesting in full of the outstanding grant and (ii) extension of the exercise period until the expiration date in connection with Reporting Person's resignation from the Issuer's Board of Directors.